Monday, 14 September 2026

Injectable lots recalled over endotoxin, Lung cancer drug findings unavailable, AI workforce report lacks detail

1. 01

   Centric recalls six injectable product lots over elevated endotoxin

   Centric Compounding voluntarily recalled six lots of injectable products nationwide in the US after finding elevated endotoxin levels in the glutathione active pharmaceutical ingredient. The consumer-level recall covered Glutathione 200 mg/mL, Myer’s Cocktail and Tri-Immune Boost vials. The company issued the recall on 9 September 2026, according to FDA MedWatch. The source gives limited detail and does not identify the affected lot numbers or report any adverse events.

   via FDA MedWatch

2. 02

   Tambotatug pelitecan report lacks trial findings

   Tambotatug pelitecan has been reported in small-cell lung cancer after platinum-based therapy. However, the supplied ahead-of-print notice from the New England Journal of Medicine provides no trial results, participant details, efficacy outcomes or safety findings. The source therefore gives limited detail and does not support assessment of the treatment’s effects.

   via NEJM

3. 03

   AI’s clinical workforce effects raised in ahead-of-print publication

   Artificial intelligence and the future of the clinical workforce are the stated focus of an ahead-of-print New England Journal of Medicine publication. The source provides no details about the publication’s arguments, evidence or implications for healthcare delivery and workforce planning.

   via NEJM

4. 04

   Academic physician staffing model proposed for Indian Health Service

   An academic physician staffing model has been proposed for the Indian Health Service in an ahead-of-print New England Journal of Medicine article. The source gives limited detail about the model, its implementation or the clinicians and communities affected.

   via NEJM

5. 05

   NEJM flags trafficked children’s health in Epstein transparency context

   The source title links the Epstein Files Transparency Act with the health of trafficked children. However, the supplied text contains no article content beyond the publication name and ahead-of-print status. It provides no findings, clinical details or reported developments to summarise.

   via NEJM

6. 06

   Celiac-artery dissection item published ahead of print

   An ahead-of-print item titled “Celiac-Artery Dissection” appeared in the New England Journal of Medicine. The source provides no clinical details, findings or information about affected patients. No further faithful summary is possible from the limited text supplied.

   via NEJM

MDDR is a news digest for medical professionals. It is not medical advice and should not be relied on for clinical decision-making.